15:19 , Sep 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Influenza virus Cell culture and mouse studies suggest inhibiting GRK2 could help treat influenza A infection. In a human alveolar basal epithelium cell line infected with human or avian strains of influenza A, an siRNA...
20:59 , Aug 29, 2018 |  BioCentury  |  Finance

Sweetening the pot

KaNDy Therapeutics Ltd. believes its first venture round as an independent company will fund development of a non-hormonal therapy for menopausal symptoms that will be ready for a Phase III trial by 2020. Longitude Capital led...
18:29 , Jun 21, 2018 |  BC Innovations  |  Emerging Company Profile

Getting past PTSD

Neurovation Labs Inc. is developing a GRIA1-targeting tracer and a small molecule therapy that could provide an objective diagnosis of PTSD and treat the underlying disease instead of just its symptoms. Post-traumatic stress disorder (PTSD) is...
19:14 , Mar 29, 2017 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Heart failure In vitro and cell culture studies identified a GRK2-inhibiting analog of Paxil paroxetine that could help treat heart failure. Structure-based design, chemical synthesis and in vitro testing of analogs of the selective serotonin...
07:00 , May 30, 2016 |  BC Week In Review  |  Clinical News

MIN-117: Phase IIa data

Top-line data from a double-blind, European Phase IIa trial in 84 patients with moderate to severe MDD showed that once-daily 0.5 and 2.5 mg oral MIN-117 for 6 weeks improved MADRS total score by magnitudes...
07:00 , Apr 21, 2016 |  BC Innovations  |  Targets & Mechanisms

Structural SERT-ainty

The publication this month of the crystal structure of the serotonin transporter unquestionably marked a technical watershed, and solved long-asked questions about why similar compounds bind the protein differently. Historically, the target revolutionized depression, spawning the...
08:00 , Feb 29, 2016 |  BC Week In Review  |  Clinical News

MIN-117: Completed Phase IIa enrollment

Minerva completed enrollment of 84 patients in a double-blind, placebo-controlled, European Phase IIa trial comparing 0.5 and 2.5 mg oral MIN-117 daily vs. 20 mg oral paroxetine daily. Minerva has exclusive, ex-Asian rights to the...
08:00 , Feb 22, 2016 |  BC Week In Review  |  Company News

GlaxoSmithKline, Competition and Markets Authority neurology, generics news

CMA imposed L45 million ($64.8 million) in fines for “pay-for-delay” conduct and agreements occurring between 2001-04 during which GlaxoSmithKline paid over L50 million ($72 million) to suppliers of generic versions of the pharma’s antidepressant Seroxat/...
03:39 , Dec 6, 2014 |  BC Extra  |  Company News

GSK staying put with established products

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) dropped its plan to divest a portfolio of U.S. and European established products after evaluating bids from potential buyers. GSK spokesperson Melinda Stubbee declined to provide further details. In July, the...
08:00 , Nov 3, 2014 |  BC Week In Review  |  Company News

GlaxoSmithKline, Dainippon Sumitomo deal

GlaxoSmithKline and Sumitomo terminated their 2012 co-promotion deal for antidepressant Paxil paroxetine CR in Japan, effective at year end. GSK will be solely responsible for providing information on Paxil CR, a once-daily Geomatrix...